Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients

This real-world study in Italy is collecting data on high-risk early breast cancer patients receiving hormone-blocking therapy plus either abemaciclib or olaparib after surgery. The goal is to understand how these treatments work in everyday clinical practice outside of a controlled trial setting. **You may be eligible if...** - You are 18 or older - You have hormone receptor-positive (HR+), HER2-negative early breast cancer that is considered high risk - You are receiving abemaciclib, olaparib, and hormone therapy as prescribed under Italian guidelines - Your cancer meets specific high-risk criteria based on stage, grade, lymph node involvement, or genetic testing results **You may NOT be eligible if...** - You are unable to understand or sign the informed consent - Your cancer does not meet the high-risk criteria specified in the study - You are currently being treated for another active cancer (except certain early-stage skin cancers or cervical in-situ) Talk to your doctor to see if this trial is right for you.